Deutsche Bank AG Boosts Stock Position in Amgen Inc. (NASDAQ:AMGN)

Deutsche Bank AG boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,213,275 shares of the medical research company's stock after purchasing an additional 8,742 shares during the period. Deutsche Bank AG owned 0.60% of Amgen worth $837,508,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Talbot Financial LLC increased its holdings in Amgen by 5.6% during the 4th quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock valued at $11,153,000 after purchasing an additional 2,274 shares in the last quarter. Ascent Wealth Partners LLC grew its stake in shares of Amgen by 0.7% during the fourth quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after purchasing an additional 64 shares during the period. Principal Financial Group Inc. grew its stake in shares of Amgen by 6.0% during the third quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock worth $204,659,000 after purchasing an additional 35,785 shares during the period. ICICI Prudential Asset Management Co Ltd lifted its holdings in Amgen by 242.2% during the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 23,999 shares of the medical research company's stock worth $6,255,000 after acquiring an additional 16,985 shares in the last quarter. Finally, PFW Advisors LLC bought a new position in Amgen during the fourth quarter worth about $1,105,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Amgen news, EVP Murdo Gordon sold 8,771 shares of the company's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the transaction, the executive vice president now owns 44,186 shares of the company's stock, valued at $13,025,590.94. This represents a 16.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the transaction, the executive vice president now directly owns 36,922 shares of the company's stock, valued at $11,240,533.68. This represents a 40.59% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 42,707 shares of company stock valued at $12,819,342. Insiders own 0.76% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on AMGN. Citigroup restated a "neutral" rating on shares of Amgen in a report on Wednesday, February 5th. Cantor Fitzgerald assumed coverage on Amgen in a report on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 target price on the stock. Mizuho upped their price objective on Amgen from $235.00 to $280.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 7th. Royal Bank of Canada dropped their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Finally, Piper Sandler increased their target price on Amgen from $310.00 to $329.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $310.23.

Amgen Stock Performance

Shares of AMGN traded up $8.90 during mid-day trading on Monday, hitting $274.76. The stock had a trading volume of 4,214,487 shares, compared to its average volume of 2,772,525. The firm has a market cap of $147.74 billion, a P/E ratio of 36.39, a PEG ratio of 2.63 and a beta of 0.51. The business has a fifty day moving average price of $296.08 and a 200-day moving average price of $289.50. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same period in the previous year, the company posted $3.96 EPS. The firm's revenue for the quarter was up 9.4% compared to the same quarter last year. On average, equities research analysts expect that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be issued a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.46%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's payout ratio is currently 86.86%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.